Background. Enhanced influenza vaccines are needed to provide improved protection for elderly individuals. The intradermal vaccination route was hypothesized to provide immunogenicity superior to that provided by the intramuscular vaccination route.
(See the editorial commentary by McElhaney and Dutz, on pages 632-4.)
Background. Enhanced influenza vaccines are needed to provide improved protection for elderly individuals. The intradermal vaccination route was hypothesized to provide immunogenicity superior to that provided by the intramuscular vaccination route.
Methods. In a multicenter, randomized study, 1107 volunteers Ͼ60 years of age received intradermal trivalent inactivated influenza vaccine containing 15 or 21 g of hemagglutinin per strain or intramuscular control vaccine. Intradermal vaccines used a novel microinjection system designed to ensure easy, convenient, consistent vaccination. The primary end points of the study were the strain-specific hemagglutination inhibition geometric mean titers (GMTs) noted 21 days after vaccination. Groups were compared using noninferiority and superiority analyses.
Results. For each strain, the GMTs noted in association with each intradermal vaccine were superior to those noted with the intramuscular control (adjusted P Ͻ .0001). Seroprotection rates, seroconversion rates, and mean titer increases were also superior for intradermally administered vaccine in all but one of the analyses undertaken. Systemic reactogenicity was comparable between routes. Local injection site reactions, particularly erythema but not pain, were more commonly associated with intradermal vaccination.
Conclusions. For the first time, the intradermal vaccination route has been used to elicit immune responses significantly superior to those noted in association with the conventional intramuscular vaccination route. This was done using an easy-to-use, reliable microinjection system. This superior response is expected to enhance annual protection against influenza in this vulnerable population.
Trial registration. Clinicaltrials.gov registry number: NCT00296829.
Influenza causes significant morbidity and mortality, particularly among older adults [1, 2] . During the 1990s in the United States, 90% of the 36,000 annual influenza-associated respiratory-and circulatory-related deaths occurred among persons aged 65 years [3] . In a recent report from England and Wales, it was estimated that 11,300 hospitalizations and 9900 deaths attributable to influenza occur annually among adults aged 65 years [4] .
This burden is even higher if secondary bacterial infections are considered [4] . Vaccination protects against influenza illness and reduces the risk of death and hospitalization associated with serious complications, such as pneumonia [5] [6] [7] [8] . However, because of immunosenescence, the immune response to vaccination decreases with age [9 -11] . In a quantitative review, the antibody response to influenza vaccination in people aged 65 years was significantly lower than that in younger adults [12] . Influenza vaccines offering enhanced immunogenicity for elderly individuals are needed to reduce the burden of disease in this increasingly large segment of the population. The use of the more efficient intradermal vaccination route could be one way to increase immunogenicity in this vulnerable population. The commonly used route for inactivated influenza vaccines is intramuscular, although other routes, such as intranasal delivery of live attenuated vaccine, are possible. Intradermal vaccination exploits the immune system of the skin by delivering antigen directly to dermal dendritic cells (professional antigenpresenting cells) that naturally amplify the immune response by efficiently migrating and presenting antigen to T cells in the draining lymph nodes. Intradermal vaccination is effective against rabies and has shown promising results with hepatitis B and influenza antigens [13] [14] [15] [16] [17] [18] . Despite the successful use of the intradermal delivery route for such vaccines as bacille CalmetteGuérin and cell-culture rabies vaccines, the use of this vaccination route has not been widely investigated because of the lack of an appropriate injection system. The standard intradermal technique for vaccine delivery (i.e., the Mantoux technique) is difficult to perform correctly and requires specifically trained and experienced personnel [19] . To overcome these issues, a new microinjection system has been developed to provide convenient and reliable intradermal injection [20] . The system features a prefilled, ready-to-use syringe with an integrated microneedle that protrudes 1.5 mm from the proximal end of the glass syringe. The syringe tip has a specifically designed needlepenetration depth limiter to ensure correct needle placement.
With the goal of developing a superior influenza vaccine for those who need it most, we compared the immunogenicity and safety of 2 doses (15 and 21 g) of an intradermal trivalent inactivated split-virion influenza vaccine with those of a conventional licensed intramuscular control vaccine, to select one vaccine for phase 3 development. Intradermal vaccinations were administered using the new microinjection system.
MATERIALS AND METHODS

Study design.
Between January and July 2006, we conducted a phase 2, multicenter, randomized, controlled, partially blind (i.e., open label for the vaccination route and double blind for the intradermal dose) study to assess the immunogenicity and safety of an intradermal inactivated split-virion influenza vaccine in elderly subjects (Clinicaltrials.gov registry number: NCT00296829). We randomly allocated subjects to receive an intradermal vaccination of either 15 or 21 g of hemagglutinin (HA) per strain or a licensed intramuscular influenza control vaccine (15 g of HA per strain). For each center, randomization lists were prepared by the statistics department of the sponsor, by use of a permuted block randomization method stratified by center. The primary objective of the study was to demonstrate (1) noninferiority and (2) that 1 of the vaccines intradermally administered using the microinjection system was superior to the intramuscular control vaccine in terms of the postvaccination geometric mean titer (GMT) against each strain.
The study was approved by the ethics committee of each center and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All subjects provided written, informed consent before enrollment.
Participants. Medically stable volunteers aged 60 -85 years were eligible to participate in the study, provided that they had none of the following characteristics: chronic illness that could interfere with the conduct or completion of the study, systemic hypersensitivity to egg or chicken proteins or any of the vaccine constituents, history of a life-threatening reaction to the study vaccine or a vaccine containing the same constituents, ongoing or recent (in the 72 h before vaccination) acute febrile illness (oral temperature, 37.5°C), congenital or acquired immunodeficiency, treatment with immunosuppressive or cancer therapy within the previous 6 months, long-term treatment with systemic corticosteroids, current alcohol abuse or drug addiction, receipt of blood or blood-derived products in the previous 3 months, influenza vaccination in the previous 6 months, receipt of any vaccination within the previous 4 weeks, or thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination.
Vaccination. All vaccines were inactivated split-virion influenza vaccines that were formulated according to the strain recommendations for the 2005 [20] . In addition to HA, the main glycoprotein responsible for inducing protective antibodies, the neuraminidase and total protein content of the 15-g intradermally administered vaccine were also determined and found to be the same as those of the 15-g intramuscularly administered vaccine. This easy-to-use system features a prefilled, ready-to-use syringe with an integral beveled, 30-gauge microneedle that protrudes 1.5 mm from the proximal end of the glass syringe. The syringe tip has a specifically designed needle-penetration depth limiter, to ensure correct placement of the needle into the dermis when the needle is inserted perpendicularly to the skin surface. The control vaccine, Vaxigrip, contained 15 g of HA per strain in each 0.5-mL dose. All vaccines were injected into the deltoid region by study nurses or investigators. Three months after vaccination, all study subjects were offered an additional vaccination with the formulation for the 2006 Southern Hemisphere influenza season.
Immunogenicity assessment. The primary end point of the study was the GMT against the 3 influenza strains at 21 days after vaccination in each group. Antibody titers were determined for each strain before vaccination and at 21 days after vaccination, by use of the hemagglutination inhibition assay, and they are presented as the highest reciprocal dilution that induced complete hemagglutination inhibition. Assays were performed under Good Laboratory Practice procedures, according to validated and Sanofi Pasteur-approved standard assay procedures based on the standard technique [21] . Chicken erythrocytes and whole antigens for each stain were used in the assays, without ether treatment of the B antigens. Each sample was tested in blinded conditions in 2 independent assay runs, and the final result was the geometric mean of the 2 values. We also assessed immunogenicity by use of the European Union Committee for Medicinal Products for Human Use (CHMP) criteria defined for annual influenza vaccines: the geometric mean ratio of the postvaccination titer to the prevaccination titer (GMTR), the seroprotection rate (i.e., the percentage of subjects with a postvaccination titer 40), and the rate of seroconversion or significant titer increase (either a postvaccination titer 40 in subjects with a prevaccination titer of Ͻ10 or a 4-fold titer increase in subjects with a prevaccination titer of 10) [22] . For the annual licensure of seasonal influenza vaccines, it is required that, for elderly individuals, 1 of the following criteria be met for each strain: a GMTR of Ͼ2, a seroprotection rate of Ͼ60%, and a rate of seroconversion or significant titer increase of Ͼ30%.
Safety and reactogenicity assessment. Subjects recorded on daily diary cards the details of any solicited reactions at the injection site (pain, pruritus, erythema, swelling, induration, and ecchymosis) and any solicited systemic reactions (fever [oral temperature, 37.5°C], headache, malaise, myalgia, and shivering) occurring within 7 days of vaccination. Subjects also recorded any unsolicited (i.e., spontaneously reported) adverse events occurring within 21 days after vaccination. Serious adverse events (SAEs) were recorded until 6 months after vaccination. In accordance with European guidelines, we also assessed the occurrence of the following reactions in the 3 days after vaccination: injection site induration of Ͼ5 cm observed for Ͼ3 days, injection site ecchymosis, body temperature of Ͼ38.0°C (i.e., oral temperature of Ͼ37.5°C) for 24 h, malaise, and shivering [22] . The severity of nonquantifiable reactions was judged by the subject as either (1) easily tolerated/noticeable but not interfering with daily activities, (2) interfering with normal behavior or activities, or (3) incapacitating/preventing daily activities.
Statistical methods. The immunogenicity of each intradermal vaccine was compared with that of the intramuscular control. To show noninferiority of each intradermal vaccine with a global power of 91%, and to allow for 10% nonevaluable subjects, we planned to enroll 1080 subjects (360 per group). To test noninferiority, we calculated for each strain the ratio of GMTs between the intradermal and intramuscular vaccination groups (GMT ID :GMT IM ). To demonstrate noninferiority, the lower bound of the 95% confidence interval (CI) of the GMT ID :GMT IM ratio had to be Ͼ0.6667 for each strain. If the intradermal vaccine was shown to be noninferior, we planned to test the superiority of each intradermal vaccine over the intramuscular vaccine. To demonstrate superiority, the 95% CI of the GMT ID : GMT IM ratio had to be Ͼ1 for at least 2 strains. For each strain, we calculated Dunnett-adjusted (for multiple comparisons) P values for each comparison with the intramuscular control group.
We compared other immunogenicity variables between the intradermal and intramuscular vaccine groups by calculating the 2-sided 95% CI of the difference or ratio between groups by use of the Wilson score method, for binomial variables, and the normal approximation method, for quantitative variables. For each variable, superiority of each intradermal vaccine over the intramuscular vaccine was determined if the 95% CI was Ͼ0 (for differences) or 1 (for ratios). We did not adjust for multiple comparisons in these secondary analyses. Other analyses were descriptive only.
Immunogenicity analyses were performed on per-protocol sets (individuals who completed the study fully compliant with the protocol) and full-analysis sets (all individuals with immunogenicity data available). Primary noninferiority testing used the per-protocol set, whereas primary superiority testing used the full-analysis set. Because the conclusions of statistical analyses were identical with both analysis sets, for convenience, all immunogenicity data reported in the present study are from the per-protocol set. Statistical analyses were performed using SAS software (version 8.2; SAS Institute).
Role of the funding source. The study was funded by a grant from Sanofi Pasteur. Through its project team, Sanofi Pasteur was involved in the design and monitoring of the study, statistical analysis, and the preparation of this manuscript.
RESULTS
Participants.
Of the 1107 subjects enrolled in the study and randomized, 1106 were vaccinated, and one withdrew consent before vaccination. Of the 1106 vaccinated subjects, 1101 completed the study to day 21 (figure 1); 5 subjects voluntarily withdrew from the study, 2 of whom cited adverse events (influenzalike symptoms) as the reason for withdrawal. The 3 vaccine groups were well matched for demographic and baseline characteristics (table 1) . Approximately 40% of each group had 1 self-reported medical condition that placed the subject at risk for complicated influenza; the most prevalent of these conditions were cardiac conditions, asthma, chronic obstructive pulmonary disease and other respiratory conditions, diabetes, or cancer. The number of each of these conditions was comparable between groups, although there were fewer cases of cardiac conditions and chronic obstructive pulmonary disease in the group receiving intramuscularly administered vaccine. Almost 85% of subjects in each group had received influenza vaccine in 2005.
Immunogenicity. Prevaccination GMTs were similar in each vaccine group and were highest for the A/H3N2 strain (table 2). After vaccination, GMTs against each strain increased in all groups and were higher in the intradermal groups. The immune response to each of the intradermal vaccines was noninferior to the response to the control vaccine for all 3 strains, enabling superiority to be tested. Superiority analysis revealed that, for all 3 strains, the postvaccination GMTs in each group given an intradermally administered vaccine were significantly higher than those noted in the control vaccine group (adjusted P Ͻ .0001) (table 2). Postvaccination GMTs in each intradermal group were 48%-70% higher than those in the control group. Both intradermally administered vaccines were therefore superior to the intramuscularly administered control vaccine in terms of the GMT noted 21 days after vaccination.
The superior immune responses elicited by vaccine administered via the intradermal route were also apparent from the CHMP immunogenicity end points (figure 2). For each strain and for each intradermally administered vaccine, the seroprotection rate, the rate of seroconversion or significant titer increase, and the GMTR were significantly higher than those associated with the intramuscularly administered control vaccine, except for the rate of seroprotection against A/H1N1 in the group given the 15-g intradermally administered vaccine, which did not reach significance. Because the different vaccination routes might theoretically affect differently those subjects who had received vaccination the previous season and those who had not, a subanalysis was performed to compare the seroprotection rates noted in the groups given 15 g intradermally and 15 g intramuscularly, with the 2005 season vaccination status considered to be a covariate. No significant effects of the prior vaccination status on the superiority analyses were detected. In Figure 1 . Flow of subjects through the study up to day 21. AE, adverse event; ID, intradermal; IM, intramuscular. each vaccination status subgroup, differences between vaccine groups were comparable with those shown in figure 2, although, because of the small sample size of the "no prior vaccination" subgroups, differences between vaccine groups were no longer significant (data not shown).
Considering the European Medicines Agency immunogenicity criteria for all 3 strains, both intradermally administered vaccines met not only the requirements defined for adults aged Ͼ60 years but, also, the more stringent requirements defined for younger adults (i.e., a seroprotection rate Ͼ70%, a rate of seroconversion or significant titer increase Ͼ40%, and a GMTR Ͼ2.5) (figure 2). In all cases, both the point estimate and the lower bound of the 2-sided 95% CI exceeded the requirement (figure 2). In comparing the 2 intradermally administered vaccine groups, although the 21 g of candidate vaccine appeared to result in higher responses than did the 15 g of candidate vaccine for some of the criteria (figure 2), the differences were not significant. Safety and reactogenicity. The incidence of reactions listed in the CHMP guideline within 3 days of vaccination (most commonly, malaise and injection site ecchymosis) was comparable to that noted in the 3 vaccine groups (table 3) . Induration of Ͼ5 cm that lasted for Ͼ3 days was not observed in any group.
Among the wider list of solicited injection site reactions, erythema, swelling, induration, and pruritus were more frequently observed in the 7 days after intradermal vaccination than in the 7 days after intramuscular vaccination (table 4) . In all vaccine groups, most injection site swelling, induration, or ecchymosis reactions were Ͻ2.5 cm in diameter. Erythema was more frequently Ͼ2.5 cm after intradermal vaccination. The majority of subjects who reported pruritus considered it to be easily tolerated. Injection site pain occurred at similar rates in each group and was easily tolerated in most cases. More than 95% of solicited injection site reactions started in the 3 days after vaccination in each group.
The incidence of solicited systemic reactions was comparable between groups (table 4). In most cases, onset occurred within 3 days of vaccination. Of the subjects reporting systemic reactions, most considered reactions to be "noticeable but did not interfere with daily activities," and most reactions lasted 3 days. Unsolicited adverse events occurring within 21 days of intradermal vaccination and considered to be vaccination related were most commonly general disorders and conditions at the administration site (such as injection site warmth), which affected 2.7% of subjects in each group given intradermally administered vaccine versus 0.8% of subjects given intramuscularly administered vaccine.
Table 2. Comparison of anti-hemagglutinin geometric mean titers (GMTs) of antibodies to influenza virus before and after intradermal (ID) or intramuscular (IM) vaccination and results of the noninferiority and superiority analyses, by vaccine route and dose.
During the 6 months of follow-up, 83 severe adverse events were reported for 69 subjects, including 4 deaths that were considered to be unrelated to vaccination; 2 of these deaths, which were due to multiform glioblastoma and coronary artery disease, occurred after intradermal vaccination, and the other 2 deaths, which were due to acute myeloid leukemia and myocardial infarction, occurred after intramuscular vaccination. All but one severe adverse event were unrelated to vaccination. The one severe adverse event that was considered to be possibly vaccination related occurred in a 68-year-old man (in the group receiving the intradermally administered 15-g vaccine) who received a diagnosis of brachial neuritis, which is a recognized event after inactivated influenza vaccination.
DISCUSSION
We have shown, for what we believe to be the first time, that the intradermal vaccination route can be used to provide immunogenicity that is significantly superior to that achieved using conventional intramuscular vaccination. After intradermal microinjection, the immune responses to inactivated influenza vaccine in this population of medically stable, noninstitutionalized, elderly adults with a range of chronic conditions were superior to the immune responses of such individuals to a licensed, nonadjuvanted intramuscular vaccine. Furthermore, intradermal vaccination induced immune responses that satisfied not only the regulatory immunogenicity requirements defined for the elderly individuals but, also, the higher requirements defined for younger adults [22] .
High hemagglutination inhibition antibody levels are associated with protection against illness [23] [24] [25] [26] [27] [28] [29] [30] [31] . Although this association has not been studied specifically in older adults, and although the precise nature of the relationship between titers and protection is unclear, it has been argued that an influenza vaccine that is able to reduce the number of subjects with a poor or low response may provide added clinical benefit [32] . A titer of 40 is considered to be indicative of a 50% reduction in the risk of contracting influenza, with higher titers associated with higher levels of protection (e.g., GMTs of 120 -160 are associated with a 90% reduction in risk) [33] . The significantly higher seroprotection rates and GMTs associated with intradermal vaccination versus intramuscular vaccination in our study can therefore be expected to translate into higher levels of clinical protection.
We evaluated 2 intradermal doses: both the standard quantity of antigen contained in conventional intramuscular vaccines (15 g of HA per strain) and a higher-dose vaccine (21 g). We found that the 21-g dose did not provide a significant immunological benefit, compared with the lower dose: both were comparably superior to the intramuscular control vaccine. On the basis of these results, the 15-g intradermally administered vaccine dose was selected for phase 3 clinical trials in elderly individuals.
The observed superior immunogenicity of intradermal immunization is consistent with the view of the skin as a highly effective part of the immune system. To serve this function, the dermis is characterized by a dense network of dendritic cellsoften referred to as "nature's adjuvant"-and an extensive lymphatic system that both contribute to efficient migration and presentation of antigen in the draining lymph nodes, resulting in a strong adaptive immune response [34 -36] .
This is not the first study of influenza vaccination via the intradermal route: Van Gelder and colleagues [37] tested this route as early as 1947, just 2 years after the commercial availability of the first influenza vaccines in the United States, and it has attracted renewed interest in more recent years [15] [16] [17] [18] 38] . A significant difference in our approach, compared with previous studies or, indeed, with our knowledge of any intradermal vaccine study, is that, for the first time, we sought to use the intradermal route to provide a vaccine with superior immunogenicity for a segment of the population (individuals aged Ͼ60 years) that has the greatest need for protection against influenza. Another major difference between our study and previous investigations of this vaccination route is the injection technique used. Conventional intradermal injections using standard syringes are difficult to perform reliably and consistently. In the present study, vaccine was administered using a system (the BD microinjection system) specifically designed to facilitate the accurate and consistent delivery of antigen into the dermis [20] .
In addition to intradermal vaccination, other approaches to overcoming immunosenescence have been evaluated. Recently, US researchers tested an intramuscularly administered vaccine in which the antigen dose was increased by 4-fold (to 60 g of HA per strain). They found that the postvaccination GMTs were 44%-71% higher with the high-dose intramuscularly administered vaccine than with the control vaccine [39] . This finding is almost identical to the increase observed in our study. In another approach adopted for a licensed influenza vaccine for elderly adults in Europe, an adjuvant is used to increase the immune response and has been shown to increase postvaccination GMTs by 17%-77% [40] . We have shown that delivering inactivated influenza vaccine into the dermis significantly increases the immune response without requiring a significantly higher antigenic dose and without resorting to the use of an adjuvant.
Considering systemic reactogenicity within the first week after vaccination, reactions were neither more frequent nor more severe after intradermal vaccination than after intramuscular vaccination. Similarly, the incidence and severity of injection site pain or ecchymosis were comparable between groups. The higher frequency of other injection site reactions, particularly erythema, associated with intradermal vaccination is in line with that noted in previous reports, and it was anticipated. Indeed, 1 at injection site injection of a vaccine just below the skin surface is likely to result more frequently in visible injection site reactions than is injection of a vaccine deep in the muscle [17, 18, 38] , and such reactions are likely to reflect the underlying inflammatory or immunological response in the skin. Importantly, these local reactions were not associated with a higher incidence or severity of injection site pain, and most reactions lasted for 3 days or less. A qualification of this study is that, because of ethical reasons associated with the design of this phase 2 study, most subjects had received the same vaccine intramuscularly Ͻ1 year previously. This meant that prevaccination titers were relatively high, and it implies that the observed immune response to vaccination could be considered to be more of a booster response than that which occurs in routine practice. However, because any such effect would apply equally to each of the 3 groups, there is no reason to suggest that the superiority of intradermal vaccination observed in the present study would not also be seen in association with a usual annual influenza vaccination.
In the present phase 2 study with a large sample size, we demonstrated that, when influenza vaccine was given intradermally by use of a new, easy-to-use microinjection system, the antibody responses elicited in adults Ͼ60 years of age were significantly superior to those elicited by conventional, intramuscularly delivered influenza vaccine. The results satisfied CHMP immunogenicity requirements for older adults and, also, for younger adults. Intradermal influenza vaccination performed using the microinjection system is expected to provide increased protection against influenza infection and its associated complications in elderly adults.
